Spondyloarthritis & psoriatic arthritis
Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 Group in Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment Recommendations
An erratum to this article was published (J Rheumatol, Dec 2022 ↗)
Methodological detailsGRADE-informed approach, consensus meetings, RCTs from February 19, 2013, to August 28, 2020 reviewed, Working group of clinicians and patient research partners
- GRADE-informed approach
- Consensus meetings
- RCTs from February 19, 2013, to August 28, 2020 reviewed
- Working group of clinicians and patient research partners
Recommendations
As issued by the authors
- strongly recommends
Treatment-naïve: Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) (MTX, SSZ, LEF) and phosphodiesterase 4 inhibitors, with regular assessment and early escalation to achieve treatment target
- strongly recommended
Treatment-naïve: bDMARDs (TNFi, IL-17i, IL-12/23i, IL-23i) and Janus kinase inhibitors (JAKi)
- strongly recommend
Inadequate response to csDMARDs: TNFi, IL-17i, IL-12/23i, IL-23i and JAKi
- strongly recommend
Prior bDMARD experience: a second TNFi, IL-17i, IL-23i and JAKi
- conditionally recommends
Adequate physical activity, smoking cessation and diet to control weight gain (evidence for nonpharmacological interventions very low)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →